Sera Prognostics (NASDAQ:SERA) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Sera Prognostics (NASDAQ:SERA) posted its quarterly earnings results on Wednesday. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01, FiscalAI reports. Sera Prognostics had a negative net margin of 34,343.16% and a negative return on equity of 41.69%. The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.03 million.

Here are the key takeaways from Sera Prognostics’ conference call:

• PRIME publication reported in January 2026 showed large clinical benefits — including a 56% fewer births before 32 weeks, 32% fewer before 35 weeks, and ~20% reduction in NICU admissions — providing RCT-level evidence the company will use to drive adoption and payer discussions.
• Commercial traction accelerated in 2025 with engagement expanding to 13 states, active discussions with ~10 payers, two live partner programs, and a target of 15–17 states and 5–7 partner programs by year-end 2026 to generate outcomes and economic data.
• The company is pursuing a European market entry, working toward CE marking with dossiers planned in the coming months and supportive expert commentary, but regulatory approval and commercialization timing remain uncertain.
• Revenue remains immaterial (FY2025 revenue ~$81,000, Q4 revenue $10,000) and the company reported a FY2025 net loss of ~$31.9M, underscoring early-stage commercial risk and continued reliance on evidence/coverage milestones to drive meaningful revenue.
• Sera ended 2025 with ~$95.8M in cash and securities, expects runway into 2028, is reallocating spend from R&D to commercial activities, and reestablished an ATM for optionality while stating no immediate plans to issue shares.

Sera Prognostics Price Performance

Shares of SERA stock opened at $1.91 on Thursday. The stock has a market cap of $73.72 million, a PE ratio of -2.48 and a beta of 1.01. The stock has a 50-day moving average of $2.68 and a 200-day moving average of $3.02. Sera Prognostics has a one year low of $1.37 and a one year high of $4.20.

Analyst Upgrades and Downgrades

A number of research firms have commented on SERA. Jefferies Financial Group raised shares of Sera Prognostics to a “strong-buy” rating in a report on Monday, December 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Sera Prognostics in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Sera Prognostics currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.00.

Insiders Place Their Bets

In related news, CEO Zhenya Lindgardt sold 22,639 shares of the business’s stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $1.90, for a total transaction of $43,014.10. Following the completion of the transaction, the chief executive officer owned 741,287 shares in the company, valued at approximately $1,408,445.30. The trade was a 2.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last 90 days, insiders have sold 57,133 shares of company stock worth $115,794. 13.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Sera Prognostics

Several large investors have recently bought and sold shares of SERA. Squarepoint Ops LLC boosted its position in shares of Sera Prognostics by 8.9% during the third quarter. Squarepoint Ops LLC now owns 93,063 shares of the company’s stock worth $285,000 after purchasing an additional 7,643 shares in the last quarter. Citadel Advisors LLC increased its position in shares of Sera Prognostics by 1.9% in the 3rd quarter. Citadel Advisors LLC now owns 653,746 shares of the company’s stock valued at $2,000,000 after buying an additional 12,439 shares in the last quarter. Lido Advisors LLC bought a new stake in shares of Sera Prognostics in the 3rd quarter valued at $68,000. Cetera Investment Advisers acquired a new stake in Sera Prognostics during the 4th quarter worth $74,000. Finally, Qube Research & Technologies Ltd acquired a new stake in Sera Prognostics during the 2nd quarter worth $92,000. Institutional investors own 54.64% of the company’s stock.

Sera Prognostics News Summary

Here are the key news stories impacting Sera Prognostics this week:

• Positive Sentiment: PRIME randomized controlled trial published showing the PreTRM® blood test reduces earliest preterm births and newborn complications — a major clinical validation that supports future adoption, reimbursement discussions and commercial credibility. SERA PROGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS
• Positive Sentiment: Management outlined an explicit commercial expansion plan to scale partner programs to 15–17 states by year‑end 2026 and said the company expects to maintain cash runway through 2028 — reduces near‑term dilution risk and signals a path for revenue growth. Sera Prognostics outlines plan to expand partner programs to 15–17 states by year-end 2026 while maintaining cash runway through 2028
• Positive Sentiment: Outlets highlight “strong 2025 performance” and positioning for commercial success, echoing management’s messaging around commercial traction and the PRIME data as a multi‑quarter growth catalyst. Sera Prognostics Sets Stage for Commercial Success with Strong 2025 Performance
• Neutral Sentiment: Earnings and conference‑call transcripts are available — management discussed execution priorities, commercial rollout and the PRIME results; read the full call for color on timing of partner rollouts and any guidance detail. Sera Prognostics Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 revenue materially missed expectations (reported ~$0.01M vs. ~$0.03M consensus) and the company continues to show very large negative margins and negative ROE — near‑term commercial revenue remains minimal, which likely drove the sell‑off despite the EPS beat. Sera Prognostics Inc. (SERA) Reports Q4 Loss, Lags Revenue Estimates
• Negative Sentiment: Market summaries note the company’s steep negative net margin and continued operating losses — investors focused on lack of near‑term revenue traction are weighing this against the long‑term clinical data. Sera Prognostics Trading / Earnings Summary

Sera Prognostics Company Profile

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.